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Sensoryneuronopathies(SNs)areaspeciﬁcsubgroupofperipheralnervoussystemdiseasescharacterizedbyprimarydegeneration
of dorsal root ganglia and their projections. Multifocal sensory symptoms often associated to ataxia are the classical features of
SN. Several diﬀerent etiologies have been described for SNs, but immune-mediated damage plays a key role in most cases. SN
may herald the onset of some systemic autoimmune diseases, which further emphasizes how important the recognition of SN is in
clinicalpractice.Wehavethusreviewedavailableclinical,neurophysiological,andtherapeuticdataonautoimmunedisease-related
SN, namely, in patients with Sj¨ ogren’s syndrome, autoimmune hepatitis, and celiac disease.
1. Overview of Sensory Neuronopathies
1.1. Deﬁnition and Historical Aspects. Sensory neuronopa-
thies or ganglionopathies (SNs) constitute a speciﬁc sub-
group of peripheral neuropathies characterized by primary
andselectivedorsalrootganglia(DRG)neuronaldestruction
[1–3]. Degeneration of DRG “T-shaped” neurons and their
projections, both central and peripheral, often results in
a multifocal pattern of sensory deﬁcits [4, 5]. This is in
contrast to the usual length-dependent pattern found in
most polyneuropathies. Although relatively rare, SN should
be included in the diﬀerential diagnosis of predominantly
sensory or ataxic neuropathies. On clinical grounds, recog-
nition of SN is important because it reduces the number of
etiologies to be investigated and also because some of these
SN-etiologies are amenable to eﬀective treatment [6].
SNs were ﬁrst described in 1948 by Denny-Brown in
two patients with bronchial carcinoma that developed acute-
onset predominantly sensory peripheral neuropathy involv-
ing arms, legs, face, and tongue [7]. Postmortem analysis
showed a massive and selective destruction of DRG neu-
rons. This description also pointed for the ﬁrst time to
the possible association between SN and neoplasia, which
later proved to be true. In the next years, Dyck et al.
described DRG histological damage in patients followed
up at the Mayo Clinic due to peripheral neuropathy of
unknown etiology [8]. Since then, several mechanisms have
been proposed to explain DRG destruction in patients with
SN, including genetic predisposition, drug-related toxicity,
infections, and immune-mediated damage [2, 9]. The latter
mechanism probably takes part in most patients with SN,
and several autoimmune systemic diseases have been asso-
ciated with SN. In this setting, our scope is to review clinical,
pathophysiological, and therapeutic aspects of SN related to
Sj¨ ogren’s syndrome (SS), celiac disease (CD), and autoim-
mune hepatitis. These are the most frequent autoimmune
diseases associated with SN.
1.2. Epidemiology. SNs are traditionally considered rare dis-
orders, but underdiagnosis is certainly a problem [1]. Most
availableepidemiologicaldatarefertoparaneoplasticandSS-
related SN [2, 9, 10]. Overall, paraneoplastic neurological
syndromes are uncommon and aﬀect nearly 0.01% of all
oncologicpatients[10].SNisthemostfrequentparaneoplas-
ticsyndromeandrepresentsaround20%ofallparaneoplasia
in a recent European report [11]. SS is the most frequent
immune-mediated disease related to SN [12]. Some authors
estimate that 10% of all patients with SS will ultimately
develop a SN. Unfortunately, 50% of the cases with SN are
still labeled as idiopathic [1, 13, 14].
1.3. Pathophysiology. Capillaries that supply DRG neurons
have a leaky basement membrane, which enable the passage2 Autoimmune Diseases
ofinﬂammatorycells,toxins,andproteins.Thisexplainswhy
DRG neurons are vulnerable to such distinct mechanisms of
damage [9]. In immune-mediated SN, most available data
support the concept of direct inﬂammatory damage to DRG
neurons mediated by CD8 T lymphocytes [3, 5, 9, 14–16].
H u m o r a ld y s f u n c t i o ns e e m st op l a yam i n o rr o l ei nm o s t
forms of SN, but anti-GD1b antibodies were associated to
SN in cell and animal-based models [17, 18]. In addition,
rare patients with SN present high serum titers of anti-GD1b
[19].
Interestingly, immune mechanisms have been lately de-
scribed in patients with idiopathic SN as well. We have
recentlyfoundhighIL-17expressioncombinedwithreduced
IL-27 expression in CSF lymphocytes. There was also an
increase in CD8 lymphocyte proportion, but not CD4, in
the blood and CSF of those patients with disease duration
smaller than 5 years when compared to those with duration
longer than 5 years [20].
1.4. Clinical Aspects. SN manifestations are often disabling,
but the speciﬁc symptoms depend on the type of involved
ﬁbers [9]. Deﬁcits are often multifocal and extend to
both proximal and distal regions of the limbs; all sen-
sory modalities—pain, temperature, sense position, and
vibration—may be compromised during disease course [2].
Large myelinated ﬁbers that convey sense position and
vibration are predominantly damaged in SN. This leads to
gait ataxia and widespread arreﬂexia [1, 2]. Some patients
present pseudoathetotic hand movements. Whenever small-
and medium-sized neurons degenerate, pain and burning
allodynia also appear [1, 2]. Motor system examination
is usually unremarkable. Nystagmus is not frequent, but
autonomic dysfunction may be found. There are reports
of tonic pupils, orthostatic hypotension, gastrointestinal
symptoms, and erectile dysfunction [4].
There are also some etiology-speciﬁc ﬁndings such as
limbic encephalitis that is characterized by recent memory
deﬁcits, behavioral changes, and seizures and are found in
20–30% of patients with anti-Hu paraneoplastic syndrome
[10]. Friedreich’s ataxia shows typical feet deformities, severe
kyphoscoliosis and, square-wave jerks [21].
Clinicalcoursemayalsobeusefultodiﬀerentiateautoim-
mune/idiopathic causes from paraneoplastic ones. Chronic
course is more common in idiopathic disease whereas an
abrupt onset is typically seen in paraneoplastic or autoim-
mune SN [2, 3]. In contrast to other immune-mediated neu-
ropathies, SN hardly presents a remitting-recurrent course.
1.5. Diagnostic Tests. SN has a distinctive clinical picture,
but diagnosis often relies on complementary workup. This
includes nerve conduction studies, neuroimaging, and path-
ological analyses.
1.5.1. Nerve Conduction Studies (NCSs). NCS are the most
useful tests in the evaluation of suspected SN [6]. NCSs clas-
sically show a sensory neuropathy without a distal worsening
gradient towards the legs. Sensory NCSs reveal widespread
reduction of sensory action potential amplitudes combined
with normal conduction velocity. Asymmetric responses are
typical of SN. Motor NCSs are often normal, but at least 18%
of patients show reduced amplitudes of compound muscle
action potentials, especially at peroneal and tibial nerves [6].
Electromyography is usually normal as well. However, some
patients present an abnormal recruitment pattern of motor
units that is especially evident during maximal activation.
Blink reﬂex study is another useful tool because it may help
to diﬀerentiate paraneoplastic versus non-paraneoplastic SN
[22].
1.5.2. Neuroimaging. Magnetic resonance imaging (MRI) is
a sensitive technique to diagnose patients with SN, especially
those with long disease duration. This is because DRG
damage leads to degeneration of their central projections—
gracile and cuneate fasciculi—which results in¡?ehlt?¿spinal
cord atrophy and gliosis. Cervical spinal cord MRI scans
thereforeshowhyperintenseT2-weightedlesionsatposterior
columns and volumetric reduction in chronic SN [23]. The
combination of such MRI ﬁndings and the typical NCS
abnormalities is virtually diagnostic of SN.
1.5.3. Pathology. Excisional biopsy with histological analysis
of DRG is the gold standard diagnostic method for SN [5].
Despite this, it is seldom performed because it is invasive
and requires trained neurosurgeons. Histological ﬁndings
are neuronal loss, the Nageotte nodules, and mononu-
clearinﬁltrates.InparaneoplasticSN,immunohistochemical
analysisshowsintraneuralIgGdepositswithoutcomplement
deposits [5].
Sural nerve biopsy reveals loss of large and small ﬁbers
in SN, but the pattern is similar to that found in the length-
dependent neuropathies. Skin biopsy with quantiﬁcation of
intraepidermal nerve ﬁber density has been recently sug-
gested as a useful tool. This technique shows a reduced ﬁber
density without a distal gradient in SN [24].
1.6. Diagnostic Criteria. Asbury and Brown were the ﬁrst to
propose clinical and electrophysiological criteria for SN in
the early 90s. Asbury’s criteria relied upon the dispropor-
tionate sensory involvement and the non-length-dependent
distribution of deﬁcits [3, 25, 26]. Although clinically useful,
these were never validated so that alternative criteria were
recentlypublished and validated by Camdessanch´ eetal .Th i s
new proposal is a score-based table that includes not only
clinical and neurophysiological data, but also cervical MRI
and pathological ﬁndings [3].
2. Speciﬁc Autoimmune-Disease-RelatedSN
2.1. Sj¨ ogren’s Syndrome. Primary Sj¨ ogren’s syndrome (SS)
is a systemic autoimmune disease that aﬀects 1-2% of the
population[27].Thecoreclinicalﬁndingsarexerophthalmia
and xerostomia (sicca syndrome), but visceral involvement
such as pneumonitis, renal tubular acidosis, and pancreatitis
also takes place [28]. Several neurological manifestations are
associated with SS, including acute myelitis, neuromyelitis
optica [29], and brainstem disease [1]. Peripheral nervousAutoimmune Diseases 3
system is damaged in about 50% of those patients with SS-
related neurological disease [2]. SS-related peripheral nerve
damage may present as cranial neuropathy (trigeminal),
mononeuritis multiplex, radiculoneuropathy, painful small
ﬁber neuropathy, autonomic neuropathy (with anhidrosis),
and SN [30].
Recent data indicate that 15–39% of all patients with
SS-related neuropathies actually have SN [2]. SN usually
antedates the diagnosis of SS. Most aﬀected patients are in
their60sor70s(meanageof64.9years)andpresentsubacute
diseaseoverweeksorfewmonths[31].InSS-relatedSN,sen-
sory disturbances are often unilateral or strikingly asymmet-
ric. Upper limbs are predominantly aﬀected, but the trunk,
face, or lower limbs are often involved as well [2]. Sensory
ataxia and widespread arreﬂexia are conspicuous ﬁndings,
but pain or painful dysaesthesias are only found in 50% of
these patients. Trigeminal involvement has been reported in
30% of the subjects and pseudoathetoid hand movements
in a smaller proportion of cases. Dysautonomic symptoms
are frequent, contribute to overall disability and may present
as hypo/anhidrosis, tonic pupils, and gastrointestinal and
cardiovascular dysfunction [2, 30].
Nerve conduction studies typically show widespread re-
duction of sensory nerve action potential amplitudes, but
no signiﬁcant reduction of conduction velocity. In some
patients, abnormalities are asymmetrical and median nerves
maybemoreseverelycompromisedthansuralnerves.Motor
conduction studies and needle EMG are often normal.
Somatosensory-evoked responses reveal abnormal central
conduction times which are probably due to the degenera-
tion of dorsal columns in the spinal cord [3]. This central
damage is also revealed by spinal cord MRI, which presents
T2 hyperintense lesions aﬀecting both gracilis and cuneatus
fasciculi.Morietal.haveshownthatsuchMRIabnormalities
correlate with clinical dysfunction in SS-related SN [3, 30,
32]. There is no serum marker for SS-related SN, but anti-
Huantibodiesaresometimesusefultodistinguishitfromthe
closely related paraneoplastic form of SN. In addition, anti-
Hu seropositivity suggests a paraneoplastic etiology even in
those subjects with an autoimmune disease diagnosed [33].
The pathological substrate of SS-related SN is a gan-
glionitis mediated by T CD8 lymphocytes. Recent evidence
indicates that humoral dysfunction plays a minor role.
Although the precise pathogenic cascade and the target an-
tigen are still unknown, upregulation of proinﬂamma-
tory cytokines—particularly tumor necrosis factor alpha
(TNFα)—is a key event [34].
There are no controlled trials devoted to the treatment
of SS-related SN. Most available data about therapy rely
upon small series or retrospective analyses [35]. Chen et
al. reported dramatic and sustained improvement in 2 out
of 4 patients after ﬁve to nine sessions of plasma exchange
[36]. In another study, 4 out of 5 patients with chronic
disease showed a remarkable improvement after three cycles
of IVIG (0.4g/kg for 5 consecutive days) given at 2-week
intervals [37]. In contrast, Rist et al. reviewed the use of
IVIg in peripheral neuropathies related to SS and found that
IVIG was not as eﬀective in the treatment of SS-related SN
as it was for sensory-motor neuropathies [38]. Rituximab
was lately shown to be eﬀective as an IVIG-sparing agent in
a patient with SS-related SN that responded to IVIg [39].
The TNFα antagonist inﬂiximab (3mg/kg) was reported as
beneﬁcial in a single patient with refractory SN [40]. In our
own experience, azathioprine (2-3mg/kg a day) also proved
eﬀective in occasional patients.
2.2. Autoimmune Hepatitis. Autoimmune hepatitis (AIH) is
a chronic inﬂammatory liver disease of unknown etiology.
Environmental triggers, failure of immune tolerance mech-
anisms, and genetic predisposition probably collaborate to
induce T-cell-mediated attack upon liver antigens, leading
to a progressive necroinﬂammatory and ﬁbrotic process.
Women are aﬀected more frequently than men (3.6:1), but
the disease is seen in all ethnic groups and ages [41]. The
diagnosis of AIH relies upon speciﬁc clinical and laboratory
criteria and the exclusion of other viral, genetic, and toxic
conditions [41, 42].
TheassociationofAIHwithSNwasﬁrstreportedin1993
by Merchut et al. that described a woman with AIH that
developed progressive non-length-dependent ataxic neu-
ropathy, predominantly aﬀecting the arms. Paresthesias and
ataxiafailedtoimprovewithimmunosuppression[43].Lied-
holm et al. in 1994 reported a woman with chronic persistent
hepatitis that developed sense position impairment in the
arms after the acute phase of hepatic illness. She presented
mild improvement with the therapy for hepatic disease [44].
Magy and colleagues then reported a 40-year-old woman
with AIH and paresthesias that rapidly evolved into severe
gait ataxia and global arreﬂexia. She was treated with IVIg
(0.4g/Kg/d—5 sessions), but symptoms did not improve.
Prednisolone was then started, but resulted in only partial
beneﬁt [45]. At least two additional patients were reported
since then, but detailed clinical data are not available [1,
13].
If we consider that both SN and AIH are unusual condi-
tions, these previous reports probably indicate that there is
a real association between them. However, with the available
data, one might speculate only whether there is a cause-and-
eﬀect relationship or that both diseases are organ-speciﬁc
expressions of an underlying widespread immunological
disturbance. Further studies with larger series are certainly
neededtoclarifythisissueandtodelineatetheclinicalproﬁle
of AIH-related SN.
2.3. Celiac Disease. Celiac disease (CD) is an autoimmune
disorder related to the ingestion of wheat gliadins or other
cereal prolamins by susceptible individuals. This suscepti-
bility is due to predisposing hereditary factors that include
both HLA and non-HLA genes [46]. More than 90% of
patients with CD carry the high-risk alleles HLA-DQ2 and
HLA-DQ8[47].PrevalenceofCDdependsonthepopulation
studied and varies from 1:70 to 1:500 [46–49]. The lifelong
incidence is 1:100, and any age group can be aﬀected [46].
Population-based studies in Finland also suggest that the
prevalence increases with age from 1.5% in children to 2.7%
in the elderly [50–53]. Women are preferentially aﬀected by
the disease with a 2:1 ratio [54].4 Autoimmune Diseases
The classical symptoms of CD are chronic malabsorptive
diarrhea, ﬂatulence, iron deﬁciency anemia, and weight loss,
but extraintestinal manifestations are also possible, such as
osteopenia, aphthous stomatitis, arthritis, liver failure, and
psychiatric and neurological manifestations [47–50]. In fact,
small bowel involvement is not a sine qua non condition to
establish the diagnosis of CD. Extraintestinal manifestations
may precede or even occur without overt intestinal involve-
ment.
Neurological manifestations of CD involve both central
and peripheral nervous system. They are found in 10–28%
of patients with an established diagnosis of CD [55]. Central
manifestations include ataxia (gluten ataxia [55]), headache,
epilepsy with or without parietooccipital calciﬁcations, en-
cephalopathy, myelopathy, intellectual degeneration with
attention/memory impairment, and stiﬀ-man syndrome
[48, 55–58]. Peripheral involvement is characterized by
symmetric sensory-motor axonal neuropathy, mononeuritis
multiplex, autonomic neuropathy, pure motor neuropathy,
small-ﬁber neuropathy, and SN [49, 57].
CD-related SN was recently reported by Hadjivassiliou
et al. in a large series of British patients that were regularly
followed by chronic neuropathies [57]. Out of 409 patients,
13% (53/409) had clinical and neurophysiological signs of
SN and 17 of those (12 women:5 men, 17/53 = 32%) had
serological evidence of gluten sensitivity. Biopsy-proven en-
teropathy was found in 7 patients out of the 17. In this
survey, CD-related SN thus accounted for 8% of all CD-
related neuropathies [55, 57]. Mean age of these 17 patients
was 67 years (range 47–85), and mean age at onset of sensory
symptomswas58years.Inthisstudy,mild/moderatesensory
ataxia was the usual chief manifestation of CD-related SN.
In another study, Brannagan III et al. reported 8 patients
withCDthatdevelopedSNbutwithpredominantsmallﬁber
involvement [49]. These patients had non-length-dependent
reduction of intraepidermal nerve ﬁber density, and their
symptoms included asymmetrical numbness or paresthesias
involving limbs, hands, feet, and face as well as mild to mod-
erate sensory ataxia [49].
CD is a peculiar autoimmune disease because the trig-
gering antigen, gluten, is already known [57]. The neuro-
logical manifestations are also immune mediated, and both
cellular and humoral responses take place [55, 58]. Several
antibodies have been associated to neurological damage such
as IgG antibodies against gliadin, IgG-deamidated gliadin
peptide antibodies, IgA antibodies against endomysium, and
IgA antibodies against diﬀerent transglutaminases, specially
the anti-transglutaminase 6 antibodies [50, 55, 56, 58].
Postmortem analyses and peripheral nerve biopsies showed
lymphocytic inﬁltrates with perivascular cuﬃng as the path-
ologic ﬁndings [57, 58].
Some patients had a slowly progressive course that was
not modiﬁed by the classical gluten-free diet (GFD). There
were occasional patients that presented disease remission
or stabilization while adherent to GFD. Immunosuppressive
therapy needed to be combined with GFD in order to induce
remission for some refractory patients [55, 57].
3. Conclusion
SN has a rather typical clinical presentation characterized
by non-length-dependent and exclusively sensory deﬁcits. It
may be associated to several autoimmune diseases, and
sometimes SN is the ﬁrst manifestation of the underlying
systemic condition. SS, AIH, and CD are the autoimmune
diseases most frequently associated to SN. Despite this, many
issues regarding the mechanisms of dorsal root ganglia dam-
age in the setting of systemic autoimmunity remain unan-
swered. Further longitudinal studies with large samples of
patients are needed to delineate the pathophysiology and the
bettertreatmentoptionsforautoimmunedisease-relatedSN,
especially in association with AIH and CD.
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